BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License Biotech Investing
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance Life Science Investing
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference Life Science Investing
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules Life Science Investing
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 Life Science Investing
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026 Life Science Investing
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference Life Science Investing
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026 Life Science Investing
